Targeting Mycolic Acid Biosynthesis with Cyclic Sulfamates: A New Strategy against Mycobacterium tuberculosis

Area of Science:

• Microbiology
• Medicinal Chemistry
• Drug Discovery

Background:

• Tuberculosis (TB) remains the deadliest infectious disease globally.
• Current TB treatments are lengthy, have side effects, and face emerging drug resistance.
• Existing drugs target a limited number of bacterial pathways.

Purpose of the Study:

• To identify novel antimycobacterial agents with new mechanisms of action.
• To address the urgent need for effective treatments against multidrug-resistant TB.
• To explore cyclic sulfamate (CS) compounds as potential TB therapeutics.

Main Methods:

• Screening of cyclic sulfamate (CS) compounds for antimycobacterial activity.
• Whole genome sequencing of resistant mutants.
• Cell-wall damage reporter assays.
• Drug-target interaction modeling.
• Cell wall lipid profiling.

Main Results:

• Identified novel CS chemotypes with potent and selective activity against Mycobacterium tuberculosis (Mtb).
• Evidence strongly supports KasA inhibition as the mechanism of action for CS compounds.
• CS-resistant mutants retained susceptibility to first-line TB drugs, indicating a novel mechanism.

Conclusions:

• CS compounds represent a promising new class of antimycobacterial agents targeting the underexploited KasA enzyme.
• The study provides a foundation for medicinal chemistry optimization of CS compounds.
• This novel chemotype could lead to alternative treatment options for TB.